CARBOQUONE

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H19N3O5
Molecular Weight	321.3285
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(COC(N)=O)C1=C(N2CC2)C(=O)C(C)=C(N3CC3)C1=O

InChI

InChIKey=SHHKQEUPHAENFK-UHFFFAOYSA-N

InChI=1S/C15H19N3O5/c1-8-11(17-3-4-17)14(20)10(9(22-2)7-23-15(16)21)12(13(8)19)18-5-6-18/h9H,3-7H2,1-2H3,(H2,16,21)

HIDE SMILES / InChI

Molecular Formula	C15H19N3O5
Molecular Weight	321.3285
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3279914
Curator's Comment: Description was created based on several sources, including http://www.ndrugs.com/?s=carboquone

Carboquone (CQ) is an anticancer alkylating agent synthesized and developed by Arakawa et al. (Sankyo Co, Ltd.) in 1970, having chemical structure, 2,5-bis-(1-aziridinyl)-3-(2-carbamoyloxy-1-methoxyethyl)-6-methyl- 1,4- benzoquinone. The antitumor efficacies of CQ were reported as excellent, however, the side effects are considerably strong. Carboquone is used to treat various forms of cancer. It is indicated for the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
cell growth 21 Target ID: GO:0016049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9703365	Inhibitor 8297		0.009 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15179836	Palliative	Preclinical	Unknown Approved Use Unknown
Multiple myeloma 159 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2924889	Primary	Preclinical	Unknown Approved Use Unknown
Ovarian cancer 157 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8217372	Primary	Preclinical	Unknown Approved Use Unknown
Lung cancer 69 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10506642	Primary	Approved 8429	Carboquone Approved Use Lung cancer, malignant lymphoma, CML Launch Date 1974
Malignant lymphoma 10 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10506642	Primary	Approved 8429	Carboquone Approved Use Lung cancer, malignant lymphoma, CML Launch Date 1974
Chronic myelogenous leukemia 22 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10506642	Primary	Approved 8429	Carboquone Approved Use Lung cancer, malignant lymphoma, CML Launch Date 1974

PubMed

Title	Date	PubMed
[An anticancer drug--carboquone].	1988 Mar	3279914
Hypoxia enhances the lethality of mitomycin C and carboquone against human malignant tumor cells in vitro.	1989	2509206
Treatment of multiple myeloma with carboquone-prednisolone.	1989 Mar	2924889
Current status of oral anticancer drugs in Japan.	1999 Oct	10506642
Postoperative adjuvant use of carmofur for early breast cancer.	2003 Dec	15179836

Patents

Sample Use Guides

In Vivo Use Guide

Oral Chronic myeloid leukaemia Adult: Initial doses for remission induction: 1-2 mg daily. Maintenance: 0.25-0.75 mg every other day or twice wkly; adjust dose to maintain WBC count between 8000 and 15000/mm 3. Doses may vary depending on regimens. Oral Cancer chemotherapy Adult: 1-1.5 mg daily in 2-3 divided doses.

Route of Administration: Oral

In Vitro Use Guide

Treatment with 0.03 microM of CQ for 30 min inhibited the clonogenicity of HeLa cells by 41.5%.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:24:02 GMT 2023` Edited by `admin` on `Fri Dec 15 16:24:02 GMT 2023`
Record UNII	1CB0HBT12C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CARBOQUONE

Official Name

English

CARBOQUONE [JAN]

Common Name

English

2,5-BIS(1-AZIRIDINYL)-3-(2-HYDROXY-1-METHOXYETHYL)-6-METHYL-P-BENZOQUINONE CARBAMATE (ESTER)

Common Name

English

carboquone [INN]

Common Name

English

CARBOQUONE [MI]

Common Name

English

CARBOQUONE [MART.]

Common Name

English

ESQUINON

Brand Name

English

Carboquone [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

L01AC03